EYEN
Open
–
Prev. Close
–
High
–
Low
–
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The company is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
emptyResult
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The company is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
Recently from Cashu
Eyenovia Stock Update: Key Developments and Market Performance Insights
Please provide the text you would like me to summarize, and I'll be happy to assist you!
Eyenovia: Leading Innovations in Ophthalmic Therapeutics Transforming Eye Care Solutions
Eyenovia's Advancements in Ophthalmic Therapeutics: A Game Changer in Eye Care Eyenovia, a pioneer in the field of ophthalmic therapeutics, continues to make significant strides that position it as a…
Eyenovia: Pioneering Innovative Ophthalmic Solutions for Enhanced Eye Care and Patient Compliance
Eyenovia's Innovative Approach to Ophthalmic Solutions Eyenovia, a pioneering biotechnology company, focuses on the development of novel therapeutics for eye care, leveraging its proprietary delivery…
Eyenovia Stock Update: Key Developments and Insights for Investors
Please provide the specific content you would like summarized, and I'll assist you in creating the article.